Published in final edited form as:

Eur Cytokine Netw. 2012 November 1; 23(4): 191–197. doi:10.1684/ecn.2012.0319.

CHRONIC TREATMENT OF MICE WITH LEUKEMIA INHIBITORY FACTOR DOES NOT CAUSE ADVERSE CARDIAC REMODELING BUT IMPROVES HEART FUNCTION

Carlos Zgheib^{1,*}, Fouad A. Zouein^{1,*}, Mazen Kurdi^{1,2}, and George W. Booz¹

¹Department of Pharmacology and Toxicology, School of Medicine, and the Center for Excellence in Cardiovascular-Renal Research, The University of Mississippi Medical Center, Jackson, Mississippi, USA

²Department of Chemistry and Biochemistry, Faculty of Sciences, Lebanese University, Rafic Hariri Educational Campus, Hadath, Lebanon

Abstract

Recent evidence suggests that the IL-6 family cytokine leukemia inhibitory factor (LIF) is produced by cardiac cells under stress conditions including myocardial infarction and heart failure. Additionally, short term delivery of LIF has been shown to have preconditioning effects on the heart and to limit infarct size. However, cell culture studies have suggested that LIF may exert harmful effects on cardiac myocytes, including pathological hypertrophy and contractile dysfunction. Long term effects of LIF on the heart *in vivo* have not been reported and were the focus of this study. Adult male mice were injected daily with LIF (2 µg/30 g) or saline for 10 days. LIF treatment caused an approximate 11% loss in body weight. Cardiac function as assessed by echocardiography was improved in LIF-treated mice. Ejection fraction and fractional shortening were increased by 21% and 32%, respectively. No cardiac hypertrophy was seen in LIF treated mice by histology or the heart to tibia length ratio, and no cardiac fibrosis was observed. STAT3 was markedly activated by LIF in the left ventricle. Differential effects of LIF were seen in protein levels of genes associated with STAT3 in the left ventricle: levels of SOD2 and Bcl-xL were unchanged, but levels of total STAT3 and MCP-1 were increased. There was a trend towards increased expression of miR-17, miR-21, and miR-199 in the left ventricle of LIF-treated mice, but changes were not statistically significant. In conclusion, effects of chronic LIF treatment on the heart, though modest, were positive for systolic function, and adverse cardiac remodeling was not observed. Our findings thus lend further support to recent proposals that LIF may have therapeutic utility in preventing injury to or repairing the myocardium.

Keywords

Cardiac remodeling; cytokine; cardiac dysfunction; JAK STAT signaling; cardiac repair; cardiac hypertrophy

INTRODUCTION

Leukemia inhibitory factor (LIF) is a member of the interleukin 6 (IL-6) family of cytokines that signal through the transmembrane protein gp130. LIF is produced by cardiac myocytes

Address Correspondence to: George W. Booz, Ph.D., FAHA, University of Mississippi Medical Center, Department of Pharmacology and Toxicology, 2500 North State Street, Jackson, MS 39216-4505, Tel: +1 601 984 4401, Fax: +1 601 984-1637, gbooz@umc.edu.

*Equal co-authors.

and is reported to have protective effects on heart cells. For example, pretreatment of adult or neonatal cardiac myocytes with LIF protected against hypoxia-reoxygenation or doxorubicin-induced injury (1–4). LIF treatment was also shown to protect against myocardial IR injury or infarction (5–6). These beneficial actions of LIF are attributed in part to the stimulation of angiogenesis and upregulation of SOD2 (MnSOD), Bcl-xL, and VEGF (2,3,5–8). In cultured cardiac myocytes, LIF was observed to protect against oxidative stress by inducing activation and translocation of Akt/protein kinase B (PKB) to mitochondria (9,10). Akt is a serine/threonine-specific protein kinase involved in both the mediator and effector phases of cardiac ischemic preconditioning (11). One target of Akt in response to LIF stimulation is hexokinase II (HK-II), which is phosphorylated and translocates to mitochondria (9). In this way, HK-II stabilizes mitochondria against oxidative stress-induced depolarization and limits mitochondrial ROS production (12).

On the other hand, LIF was also shown to have effects on the growth, metabolism, contractility, and Ca^{2+} handling of cardiac myocytes that could be characterized as disadvantageous; however, these studies relied on cultured cells or isolated muscle and thus the physiological significance of these effects is uncertain (13–22). Numerous reports have implicated IL-6 in the adverse cardiac remodeling associated with hypertension and myocardial infarction, as well as heart failure (23–26). However, while IL-6 signals through gp130 homodimers, LIF signals through gp130 heterodimers with the LIF receptor with notable consequences, such as a more sustained activation of STAT3 with LIF (27).

From the preceding discussion, it is clear that uncertainty surrounds the long term consequences of LIF exposure on the heart. As a first step in establishing whether LIF may have therapeutic utility in preventing injury to the heart or repairing the injured myocardium, we carried out an *in vivo* study giving mice daily intraperitoneal (IP) injections of LIF (2 $\mu\text{g}/30\text{ g}$) over 10 days. Our hypothesis was that chronic treatment of mice with LIF would not adversely affect cardiac function or induce adverse cardiac remodeling.

METHODS

Materials

Antibodies for total STAT3 (Cat. #9139), pY705 STAT3 (Cat. #9131), MCP-1 (Cat. #2029), and Bcl-XL (Cat. #2764) were from Cell Signaling Technology (Danvers, MA, USA). Antibodies for SOD2 (sc-137254) and GAPDH (sc-25778/sc-166545) were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Murine recombinant LIF was from Millipore (Billerica, MA, USA). Kinase extraction buffer (BP-116K) and activated vanadate were purchased from Boston BioProducts (Worcester, MA, USA). Protease inhibitor cocktail (P8340) was from Sigma-Aldrich (St. Louis, MO, USA).

Experimental Protocol

We used male C57BL/6 mice (2–3 months old), which were divided into two groups: Saline or control group ($n = 4$) and LIF-treated group ($n = 4$). Mice were injected IP with 200 μl LIF (2 μg per 30 g body weight) or saline. Mice received one injection daily for 10 days. This dosing protocol was shown to produce a sustained increase in plasma LIF of $> 1,000\text{ U/mL}$ for approximately 3 hours that remained above baseline for longer than 6 hours in mice (28). Cardiac function was assessed by echocardiography at day 0 and 10. On day 10, mice were weighed, echocardiography was done, mice were injected, and 2 h later, hearts were harvested and weighed. The tibia was collected. Cardiac hypertrophy was assessed by measuring the heart to body weight and the heart weight to tibia length ratios; the left ventricles were processed for Western blot analysis, microRNA expression, and histology

Echocardiography

Assessment of cardiac function was done with a Vevo 770 high resolution *in vivo* imaging system (VisualSonics). Measurements were made with a 707B RMV scanhead with a center frequency of 25 MHz and a frequency band ranging from 12.5 to 37.5 MHz. The probe used was a single-element, mechanical vector probe. For the procedure, mice were maintained at 37°C and anesthesia induced with 1.5% isoflurane and oxygen (3 liters/min). Mice were placed on a prewarmed EKG transducer pad and body temperature monitored. Heart rate was monitored via the EKG transducer pad. Two-dimensional B-mode parasternal long axis views were obtained to visualize the aortic and mitral valves. The transducer was then rotated clockwise 90° to obtain parasternal short axis view. Ejection fraction (EF) and fractional shortening (FS) were analyzed and calculated using the VisualSonics advanced cardiovascular measurements package. Left ventricular (LV) wall dimensions were determined from M-mode images.

MicroRNA analysis

Total RNA was isolated from hearts and purified using miRNeasy Mini Kit from Qiagen (Cat. # 217004). To quantify miRNA levels, cDNA was reverse transcribed from total RNA samples using specific miRNA primers from the TaqMan MicroRNA Assays and reagents from the TaqMan MicroRNA Reverse Transcription kit (Applied Biosystems). The resulting cDNA was amplified by PCR using TaqMan MicroRNA Assay primers with the TaqMan Universal PCR Master Mix and analyzed with Bio-Rad's CFX96 Touch™ Real-Time PCR Detection System. Relative levels of miRNA expression were calculated by the $\Delta\Delta C_t$ method and normalization to the signal of microRNA U6.

Histology

Hearts preserved in 10% formalin were embedded in paraffin, sectioned (5 μ m thickness), and stained with Masson's Trichrome stain for collagen and myocardial morphology. Both cross and longitudinal sections (3–4 each) were prepared for each heart. Regions of the left and right ventricle were imaged with a Nikon E-600 and images collected with a 40X (NA = 0.75) objective.

Western Blots

Whole-cell lysates were prepared by scraping cells into ice-cold RIPA-based buffer with 10 mM vanadate and protease inhibitor cocktail. Lysates were cleared by centrifugation at 100,000 g for 20 min at 4°C. Samples containing equal amounts of protein in Laemmli's-SDS reducing buffer were separated by SDS-PAGE. Separated proteins were blotted onto nitrocellulose membranes and the immunoreactive bands quantified using the Li-COR Odyssey infrared imaging system.

Statistical Analysis

Results are expressed as mean $\pm$ SEM for n number of mice. Statistical significance involving single comparisons was determined by a Student's t-test. For multiple comparisons, ANOVA followed by an appropriate post-hoc test as noted was performed. A $P < 0.05$ was taken as significant.

RESULTS

LIF treatment increased STAT3 activation and total STAT3 protein levels

LIF is a potent activator of STAT3 in cardiac myocytes. As may be seen from Figure 1, the left ventricles of mice receiving LIF showed marked levels of STAT3 activation noted as the phosphorylation of either Y705 or S727 normalized to total STAT3 protein levels. In

addition, LIF-treated mice expressed higher levels of total STAT3 in the left ventricle (Fig. 1), which agrees with reports that activated STAT3 induces its own expression (29). However, no changes were seen in the expression levels of two cardiac protective proteins that others have linked to STAT3 activation in the heart, SOD2 and Bcl-xL (Fig. 2).

LIF treatment increased improved cardiac function but did not cause hypertrophy

As seen from Table 1, mice receiving LIF for 10 days lost approximately 11% in body weight, which is consistent with reports that LIF like other IL-6 family cytokines is associated with cachexia (30). However, we did not see any abnormalities in the physical appearance or behavior of mice receiving LIF. No cardiac hypertrophy was noted as indexed by the heart to body weight ratio or the heart weight to tibia length ratio (Table 1). Moreover, we did not find any changes in the left ventricular dimensions measured by echocardiography: LVIDd, left ventricular internal dimension at diastole; LVPWd, left ventricular posterior wall dimension at diastole; LVIDs, left ventricular internal dimension at systole; and LVAWd, left ventricular anterior wall dimension at diastole. On the other hand, our echocardiography results show that mice who received LIF treatment presented a significant increase in EF and FS for both individual and grouped data (Fig. 3). These findings indicate that, compared to what is already described for IL-6 (23–26), LIF did not induce hypertrophy or adverse remodeling of the heart, but had more beneficial effects on heart function and contractility.

LIF treatment did not lead to fibrosis

No gross morphological differences were observed between the saline and LIF hearts (Fig. 4). There was no fibrosis present in the LIF samples or saline controls. Also, there appeared to be no differences in cardiac myocyte morphology or myofibrillar structure between the controls and LIF-treated mice.

LIF treatment tended to increase levels of STAT3-associated microRNAs

STAT3 has been linked to the expression of three 3 miRNAs: miR-17, miR-21, and miR-199 (31). All three of these miRNAs have been implicated in cardiac function or remodeling (32,33). As seen from Figure 5, there was a trend towards increased expression of miR-17, miR-21, and miR-199 in the left ventricle of LIF-treated mice; however, these changes did not reach statistical significance.

LIF induced expression of MCP-1 protein

MCP-1 (monocyte chemoattractant protein-1), also known as chemokine (C-C motif) ligand 2 (CCL2), is a cytokine belonging to the CC chemokine family. MCP-1 is produced by macrophages and endothelial cells and plays an important role in the recruitment of inflammatory cells to sites of injury. This cytokine is upregulated in the heart during stress or injury. In the mouse, MCP-1 is heavily glycosylated and exists as a monomer or dimer (34,35). The anticipated molecular weight of the glycosylated monomer is ~30 kDa. MCP-1 can be extensively glycosylated on its C-terminus which favors formation of the dimer. Our results show that, mice who received LIF treatment expressed a higher order form of MCP-1 of ~66 kDa consistent with the glycosylated dimer (Fig. 6).

DISCUSSION

Multiple studies have reported that LIF induces a hypertrophic response in cultured cardiac myocytes (e.g., 13). However, to the best of our knowledge, whether or not LIF induces cardiac hypertrophy *in vivo* has not been determined. In the present study, we found that chronic administration of LIF did not induce cardiac hypertrophy in mice. This observation

raises the possibility that the findings on cultured cells, which after all were obtained under contrived growth conditions (including serum-starvation), may not be readily transferable to the *in vivo* situation.

We observed an increase in EF and FS with LIF treatment of mice, inducing that LIF positively affects cardiac contractility. This could have resulted from a direct effect on cardiac myocytes or an indirect effect on adrenergic control of heart function. Consistent with the first possibility is the observation that LIF was reported to increase calcium entry through the L-type channel in cultured cardiac myocytes (21). Concerning the second possibility, it should be noted that cholinergic transdifferentiation of cardiac sympathetic nerves has been ascribed to LIF in rodents (36). One may speculate that the pulsatile increases in blood levels of LIF expected in the present study (35) exerted a rebound effect on the sympathetic drive of the heart. Others have reported that IL-6 family cytokines have a negative effect on cardiac contractility due to an induction of nitric oxide synthase 2 (NOS2) (18); however, in our study no induction of NOS2 was observed (data not shown). Our findings highlight an important point that is often overlooked with regard the IL-6 family cytokines. Although these cytokines share the gp130 signaling module and activate STAT3, they may exert disparate and even contrary effects on cells/tissues. We recently proposed that this is due not only to differences in intensity and duration of STAT3 activation, but to variability in the recruitment of concurrent signals (27).

As expected we found that STAT3 was activated in hearts of mice treated with LIF. Moreover, levels of STAT3 were increased, which is consistent with reports of STAT3-induced STAT3 expression (29). Notably, no increase in expression levels of SOD2 or Bcl-xL was observed in the present study. In cultured cardiac myocytes, protective effects of LIF against oxidative stress induced by hypoxia/reoxygenation or doxorubicin were implicated in the upregulation of SOD2 and Bcl-xL, respectively (2,3,8). SOD2 protects mitochondria against oxidative stress by eliminating superoxide, while Bcl-xL is transmembrane mitochondrial protein that prevents apoptosis. LIF treatment did induce formation of MCP-1 (Fig. 6) and recent evidence indicates that MCP-1 may have direct protective effects on cardiac myocytes (37,38).

LIF treatment tended to increase levels of miR-17, miR-21, and miR-199a, although these changes did not reach statistical significance. Of the 3, evidence that STAT3 has a positive effect on the expression levels of miR-17 is perhaps the strongest; however, the role of miR-17 in the adult heart is not well studied. There is evidence to suggest that miR-17 has a role in endothelial cell proliferation (39). MiR-21 is highly expressed in cardiac fibroblasts (40). This miRNA promotes cardiac growth (41,42) and was shown to play a role in blocking apoptosis by targeting programmed cell death 4 (PCDC4) protein in hydrogen peroxide-treated cardiac myocytes (43). miR-199a was implicated in maintaining cell size of cardiac myocytes and in regulating cardiac hypertrophy (44).

In conclusion, under the conditions of the experiment, the presence of LIF did not result in the formation of fibrosis in the myocardium. Additionally, LIF did not appear to have any effect on cardiac myocyte morphology or myofibrillar integrity. Rather, the effects of chronic LIF treatment on the heart, though modest, were positive for systolic function as evidenced by an increase in EF and FS. In addition, we saw an increase in MCP-1, which may be protective, and a trend towards an increase in protective miRNAs. Our findings thus lend further support to recent proposals that LIF may have therapeutic utility in preventing injury to or repairing the myocardium.

Acknowledgments

The authors acknowledge the outstanding contribution of Dr. John Fuseler (Department of Cell Biology and Anatomy, University of South Carolina School of Medicine, Columbia, SC, USA) who performed and analyzed the histology. This work was supported by grants to MK from The Lebanese University (MK-02-2011), The Lebanese National Council for Scientific Research (CNRS;05-10-09), and The COMSTECH-TWAS (09-122 RG/PHA/AF/AC_C); and a grant from the National Heart, Lung, and Blood Institute to GWB (R01HL088101-06).

References

1. Izumi M, Masaki M, Hiramoto Y, Sugiyama S, Kuroda T, Terai K, Hori M, Kawase I, Hirota H. Cross-talk between bone morphogenetic protein 2 and leukemia inhibitory factor through ERK 1/2 and Smad1 in protection against doxorubicin-induced injury of cardiomyocytes. *J Mol Cell Cardiol.* 2006; 40:224–233. [PubMed: 16427075]
2. Negoro S, Kunisada K, Fujio Y, Funamoto M, Darville MI, Eizirik DL, Osugi T, Izumi M, Oshima Y, Nakaoka Y, Hirota H, Kishimoto T, Yamauchi-Takahara K. Activation of signal transducer and activator of transcription 3 protects cardiomyocytes from hypoxia/reoxygenation-induced oxidative stress through the upregulation of manganese superoxide dismutase. *Circulation.* 2001; 104:979–981. [PubMed: 11524388]
3. Negoro S, Oh H, Tone E, Kunisada K, Fujio Y, Walsh K, Kishimoto T, Yamauchi-Takahara K. Glycoprotein 130 regulates cardiac myocyte survival in doxorubicin-induced apoptosis through phosphatidylinositol 3-kinase/Akt phosphorylation and Bcl-xL/caspase-3 interaction. *Circulation.* 2001; 103:555–561. [PubMed: 11157722]
4. Wang F, Seta Y, Baumgarten G, Engel DJ, Sivasubramanian N, Mann DL. Functional significance of hemodynamic overload-induced expression of leukemia-inhibitory factor in the adult mammalian heart. *Circulation.* 2001; 103:1296–1302. [PubMed: 11238276]
5. Nelson SK, Wong GH, McCord JM. Leukemia inhibitory factor and tumor necrosis factor induce manganese superoxide dismutase and protect rabbit hearts from reperfusion injury. *J Mol Cell Cardiol.* 1995; 27:223–229. [PubMed: 7760346]
6. Zou Y, Takano H, Mizukami M, Akazawa H, Qin Y, Toko H, Sakamoto M, Minamino T, Nagai T, Komuro I. Leukemia inhibitory factor enhances survival of cardiomyocytes and induces regeneration of myocardium after myocardial infarction. *Circulation.* 2003; 108:748–753. [PubMed: 12860906]
7. Funamoto M, Fujio Y, Kunisada K, Negoro S, Tone E, Osugi T, Hirota H, Izumi M, Yoshizaki K, Walsh K, Kishimoto T, Yamauchi-Takahara K. Signal transducer and activator of transcription 3 is required for glycoprotein 130-mediated induction of vascular endothelial growth factor in cardiac myocytes. *J Biol Chem.* 2000; 275:10561–10566. [PubMed: 10744750]
8. Fujio Y, Kunisada K, Hirota H, Yamauchi-Takahara K, Kishimoto T. Signals through gp130 upregulate bcl-x gene expression via STAT1-binding cis-element in cardiac myocytes. *J Clin Invest.* 1997; 99:2898–28905. [PubMed: 9185513]
9. Miyamoto S, Murphy AN, Brown JH. Akt mediates mitochondrial protection in cardiomyocytes through phosphorylation of mitochondrial hexokinase-II. *Cell Death Differ.* 2008; 15:521–529. [PubMed: 18064042]
10. Miyamoto S, Purcell NH, Smith JM, Gao T, Whittaker R, Huang K, Castillo R, Glembotski CC, Sussman MA, Newton AC, Brown JH. PHLPP-1 negatively regulates Akt activity and survival in the heart. *Circ Res.* 2010; 107:476–484. [PubMed: 20576936]
11. Downey JM, Davis AM, Cohen MV. Signaling pathways in ischemic preconditioning. *Heart Fail Rev.* 2007; 12:181–188. [PubMed: 17516169]
12. Wu R, Wyatt E, Chawla K, Tran M, Ghanefar M, Laakso M, Epting CL, Ardehali H. Hexokinase II knockdown results in exaggerated cardiac hypertrophy via increased ROS production. *EMBO Mol Med.* 2012; 4:633–646. [PubMed: 22517678]
13. Nakaoka Y, Nishida K, Fujio Y, Izumi M, Terai K, Oshima Y, Sugiyama S, Matsuda S, Koyasu S, Yamauchi-Takahara K, Hirano T, Kawase I, Hirota H. Activation of gp130 transduces hypertrophic signal through interaction of scaffolding/docking protein Gab1 with tyrosine phosphatase SHP2 in cardiomyocytes. *Circ Res.* 2003; 93:221–229. [PubMed: 12855672]

14. Nicol RL, Frey N, Pearson G, Cobb M, Richardson J, Olson EN. Activated MEK5 induces serial assembly of sarcomeres and eccentric cardiac hypertrophy. *EMBO J.* 2001; 20:2757–2767. [PubMed: 11387209]
15. Nagai T, Tanaka-Ishikawa M, Aikawa R, Ishihara H, Zhu W, Yazaki Y, Nagai R, Komuro I. Cdc42 plays a critical role in assembly of sarcomere units in series of cardiac myocytes. *Biochem Biophys Res Commun.* 2003; 305:806–810. [PubMed: 12767901]
16. Fujio Y, Matsuda T, Oshima Y, Maeda M, Mohri T, Ito T, Takatani T, Hirata M, Nakaoka Y, Kimura R, Kishimoto T, Azuma J. Signals through gp130 upregulate Wnt5a and contribute to cell adhesion in cardiac myocytes. *FEBS Lett.* 2004; 573:202–206. [PubMed: 15327998]
17. Takahashi E, Fukuda K, Miyoshi S, Murata M, Kato T, Ita M, Tanabe T, Ogawa S. Leukemia inhibitory factor activates cardiac L-Type Ca^{2+} channels via phosphorylation of serine 1829 in the rabbit Cav1. 2 subunit. *Circ Res.* 2004; 94:1242–1248. [PubMed: 15044319]
18. Florholmen G, Aas V, Rustan AC, Lunde PK, Straumann N, Eid H, Odegaard A, Dishington H, Andersson KB, Christensen G. Leukemia inhibitory factor reduces contractile function and induces alterations in energy metabolism in isolated cardiomyocytes. *J Mol Cell Cardiol.* 2004; 37:1183–1193. [PubMed: 15572048]
19. Florholmen G, Andersson KB, Yndestad A, Austbø B, Henriksen UL, Christensen G. Leukaemia inhibitory factor alters expression of genes involved in rat cardiomyocyte energy metabolism. *Acta Physiol Scand.* 2004; 180:133–142. [PubMed: 14738472]
20. Florholmen G, Thoresen GH, Rustan AC, Jensen J, Christensen G, Aas V. Leukaemia inhibitory factor stimulates glucose transport in isolated cardiomyocytes and induces insulin resistance after chronic exposure. *Diabetologia.* 2006; 49:724–731. [PubMed: 16489447]
21. Hagiwara Y, Miyoshi S, Fukuda K, Nishiyama N, Ikegami Y, Tanimoto K, Murata M, Takahashi E, Shimoda K, Hirano T, Mitamura H, Ogawa S. SHP2-mediated signaling cascade through gp130 is essential for LIF-dependent I_{CaL} , $[\text{Ca}^{2+}]_i$ transient, and APD increase in cardiomyocytes. *J Mol Cell Cardiol.* 2007; 43:710–716. [PubMed: 17961593]
22. Hiraoka E, Kawashima S, Takahashi T, Rikitake Y, Hirase T, Yokoyama M. PI 3-kinase-Akt/p70 S6 kinase in hypertrophic responses to leukemia inhibitory factor in cardiac myocytes. *Kobe J Med Sci.* 2003; 49:25–37. [PubMed: 12796566]
23. Meléndez GC, McLarty JL, Levick SP, Du Y, Janicki JS, Brower GL. Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. *Hypertension.* 2010; 56:225–231. [PubMed: 20606113]
24. Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, Sawyer DB, Levy D, Wilson PW, D'Agostino RB. Framingham Heart Study. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. *Circulation.* 2003; 107:1486–1491. [PubMed: 12654604]
25. Gullestad L, Aukrust P. Review of trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches. *Am J Cardiol.* 2005; 95:17C–23C.
26. Oikonomou E, Tousoulis D, Siasos G, Zaromitidou M, Papavassiliou AG, Stefanadis C. The role of inflammation in heart failure: new therapeutic approaches. *Hellenic J Cardiol.* 2011; 52:30–40. [PubMed: 21292605]
27. Zgheib C, Zouein FA, Kurdi M, Booz GW. Differential STAT3 Signaling in the Heart: Impact of Concurrent Signals and Oxidative Stress. *JAK-STAT.* 2012; 1:102–111.
28. Metcalf D, Nicola NA, Gearing DP. Effects of injected leukemia inhibitory factor on hematopoietic and other tissues in mice. *Blood.* 1990; 76:50–56. [PubMed: 2114187]
29. Cheon H, Yang J, Stark GR. The functions of signal transducers and activators of transcriptions 1 and 3 as cytokine-inducible proteins. *J Interferon Cytokine Res.* 2011; 31:33–40. [PubMed: 21166594]
30. Matthys P, Billiau A. Cytokines and cachexia. *Nutrition.* 1997; 13:763–770. [PubMed: 9290087]
31. Kohanbash G, Okada H. MicroRNAs and STAT interplay. *Semin Cancer Biol.* 2012; 22:70–75. [PubMed: 22210182]
32. Mendell JT. miRiad roles for the miR-17-92 cluster in development and disease. *Cell.* 2008; 133:217–222. [PubMed: 18423194]

33. Topkara VK, Mann DL. Role of microRNAs in cardiac remodeling and heart failure. *Cardiovasc Drugs Ther.* 2011; 25:171–182. [PubMed: 21431305]
34. Tan JH, Canals M, Ludeman JP, Wedderburn J, Boston C, Butler SJ, Carrick AM, Parody TR, Taleski D, Christopoulos A, Payne RJ, Stone MJ. Design and receptor interactions of obligate dimeric mutant of chemokine monocyte chemoattractant protein-1 (MCP-1). *J Biol Chem.* 2012; 287:14692–14702. [PubMed: 22396538]
35. Yao Y, Tsirka SE. The C terminus of mouse monocyte chemoattractant protein 1 (MCP1) mediates MCP1 dimerization while blocking its chemotactic potency. *J Biol Chem.* 2010; 285:31509–31516. [PubMed: 20682771]
36. Kanazawa H, Ieda M, Kimura K, Arai T, Kawaguchi-Manabe H, Matsuhashi T, Endo J, Sano M, Kawakami T, Kimura T, Monkawa T, Hayashi M, Iwanami A, Okano H, Okada Y, Ishibashi-Ueda H, Ogawa S, Fukuda K. Heart failure causes cholinergic transdifferentiation of cardiac sympathetic nerves via gp130-signaling cytokines in rodents. *J Clin Invest.* 2010; 120:408–421. [PubMed: 20051627]
37. Morimoto H, Hirose M, Takahashi M, Kawaguchi M, Ise H, Kolattukudy PE, Yamada M, Ikeda U. MCP-1 induces cardioprotection against ischaemia/reperfusion injury: role of reactive oxygen species. *Cardiovasc Res.* 2008; 78:554–562. [PubMed: 18267955]
38. Morimoto H, Takahashi M, Izawa A, Ise H, Hongo M, Kolattukudy PE, Ikeda U. Cardiac overexpression of monocyte chemoattractant protein-1 in transgenic mice prevents cardiac dysfunction and remodeling after myocardial infarction. *Circ Res.* 2006; 99:891–899. [PubMed: 16990567]
39. Bonauer A, Dimmeler S. The microRNA-17-92 cluster: still a miRacle? *Cell Cycle.* 2009; 8:3866–3873. [PubMed: 19887902]
40. Bonci D. MicroRNA-21 as therapeutic target in cancer and cardiovascular disease. *Recent Pat Cardiovasc Drug Discov.* 2010; 5:156–161. [PubMed: 20649511]
41. Cheng Y, Ji R, Yue J, Yang J, Liu X, Chen H, Dean DB, Zhang C. MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy? *Am J Pathol.* 2007; 170:1831–1840. [PubMed: 17525252]
42. Tatsuguchi M, Seok HY, Callis TE, Thomson JM, Chen JF, Newman M, Rojas M, Hammond SM, Wang DZ. Expression of microRNAs is dynamically regulated during cardiomyocyte hypertrophy. *J Mol Cell Cardiol.* 2007; 42:1137–1141. [PubMed: 17498736]
43. Cheng Y, Liu X, Zhang S, Lin Y, Yang J, Zhang C. MicroRNA-21 protects against the H₂O₂-induced injury on cardiac myocytes via its target gene PDCD4. *J Mol Cell Cardiol.* 2009; 47:5–14. [PubMed: 19336275]
44. Song XW, Li Q, Lin L, Wang XC, Li DF, Wang GK, Ren AJ, Wang YR, Qin YW, Yuan WJ, Jing Q. MicroRNAs are dynamically regulated in hypertrophic hearts, and miR-199a is essential for the maintenance of cell size in cardiomyocytes. *J Cell Physiol.* 2010; 225:437–443. [PubMed: 20458739]

Figure 1.

LIF treatment activated STAT3 in the left ventricles and increased total STAT3 levels. Mice received either 200 μ l LIF (2 μ g per 30 g body weight) or saline daily by IP injection for 10 days (4 mice per group). On the last day, hearts were extracted and the left ventricles processed for Western blot analysis for STAT3 Y705 and S727 phosphorylation, indicative of activation. Results were quantified by the Li-COR Odyssey system and normalized to STAT3 protein levels determined on the same blot (upper two panels). In a separate blot, STAT3 expression levels were normalized to GAPDH protein levels. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ (Student's t-test).

Figure 2.

LIF treatment did not change expression levels of SOD2 or Bcl-xL. Mice received either 200 μ l LIF (2 μ g per 30 g body weight) or saline daily by IP injection for 10 days (4 mice per group). On the last day, hearts were extracted and the left ventricles processed for Western blot analysis for (A) SOD2 and (B) Bcl-xL. Results were quantified by the Li-COR Odyssey system and normalized to GAPDH protein levels determined on the same blot. No difference was seen between saline- and LIF-treated mice.

Figure 3.

LIF treatment increased ejection fraction and fractional shortening. Mice received either 200 μ l LIF (2 μ g per 30 g body weight) or saline daily by IP injection for 10 days.

Echocardiography was performed the day before the first injection (Day 0) or right before the last injection (Day 10). Group data (mean $\pm$ SEM) are shown in the left panels and were analyzed by one-way ANOVA followed by Newman-Keuls (ejection fraction; * $P < 0.05$ LIF Day 10 vs. all other groups) or Tukey's (fractional shortening; * $P < 0.05$ Saline Day 10 vs. LIF Day 10) post hoc test. Fractional changes for individual mice are shown in the right panels. ** $P < 0.01$, Student's t-test.

Figure 4.

Trichrome staining of the myocardium of mice treated with saline or LIF. Saline control: (A) Typical cross-section and (B) longitudinal-section morphology of the myocardium in the left ventricle. LIF-treated: (C) Typical cross-section and (D) longitudinal-section morphology of the myocardium in the left ventricle.

Figure 5.

LIF treatment did not change expression levels of miR-17, miR-21, and miR-199. Mice received either 200 μ l LIF (2 μ g per 30 g body weight) or saline daily for 10 days (4 mice per group). On the last day, hearts were extracted and the left ventricles processed for micro-RNA extraction, cDNA synthesis, and real time PCR analysis. The values were normalized to the expression levels of micro-RNA U6.

Figure 6.

LIF treatment increased cardiac MCP-1 levels. Mice received either 200 μ l LIF (2 μ g per 30 g body weight) or saline daily for 10 days (4 mice per group). On the last day, hearts were extracted and the left ventricles processed for Western blot analysis for MCP-1. Results were quantified by the Li-COR Odyssey system and normalized to GAPDH protein levels determined on the same blot. Values are mean $\pm$ SEM, * $P < 0.05$ (Student's t-test).

Table 1

Chronic LIF treatment of mice.

	Saline	LIF
Body Weight Day 0 (g)	29.0 ± 0.6 (4)	28.0 ± 0.0 (4)
Body Weight Day 10 (g)	28.8 ± 0.5 (4)	24.8 ± 0.2 (4) ***
Heart Weight/Body Weight, mg/g	5.07 ± 0.09 (4)	5.66 ± 0.17 (4)
Heart Weight/Tibia length, mg/mm	7.69 ± 0.34 (4)	6.86 ± 0.27 (4)
LVIDd, Day 0 (mm)	4.05 ± 0.18 (4)	3.75 ± 0.35 (3)
Day 10 (mm)	4.30 ± 0.15 (4)	3.74 ± 0.07 (3)
LVPWd, Day 0 (mm)	1.00 ± 0.11 (4)	1.08 ± 0.16 (3)
Day 10 (mm)	0.76 ± 0.04 (4)	1.13 ± 0.11 (3)
LVIDs, Day 0 (mm)	2.77 ± 0.24 (4)	2.46 ± 0.18 (3)
Day 10 (mm)	2.83 ± 0.11 (4)	2.15 ± 0.14 (3)
LVAWd, Day 0 (mm)	0.86 ± 0.04 (4)	0.70 ± 0.06 (3)
Day 10 (mm)	0.77 ± 0.08 (4)	0.88 ± 0.04 (3)

LVIDd, left ventricular internal dimension at diastole; LVPWd, left ventricular posterior wall dimension at diastole; LVIDs, left ventricular internal dimension at systole; and LVAWd, left ventricular anterior wall dimension at diastole. Values are mean ± SEM for (n) number of mice.

P < 0.001 vs. LIF Body Weight Day 0 (paired t-test).